[Effects of mildronate on hemoglobin ligand spectrum in patients with ischemic heart disease complicated by coronary insufficiency].
Sakharchuk
I I
II
Starodub
N F
NF
Sisetskiĭ
A P
AP
Artiukh
V P
VP
Denisenko
G T
GT
D000368:Aged; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006333:Heart Failure / Q000097:blood*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008024:Ligands; D008297:Male; D008706:Methemoglobin / Q000032:analysis; D008763:Methylhydrazines / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D010108:Oxyhemoglobins / Q000032:analysis
D002317:Cardiovascular Agents; D006454:Hemoglobins; D008024:Ligands; D008763:Methylhydrazines; D010108:Oxyhemoglobins; C050147:3-(2,2,2-trimethylhydrazine)propionate; D008706:Methemoglobin
Vliianie mildronata na ligandnyĭ spektr gemoglobina u bol'nykh ishemicheskoĭ bolezn'iu serdtsa, oslozhnennoĭ serdechnoĭ nedostatochnost'iu.